S-adenosylmethionine (SAM-e) for the treatment of
depression in people living with HIV/AIDS

Shippy RA, Mendez D, Jones K, Cergnul I, Karpiak SE.
ACRIA (AIDS Community Research Initiative of America),
230 West 38th St, 17th Floor,
New York, NY 10018, USA.
BMC Psychiatry. 2004 Nov 11;4:38.


BACKGROUND: This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen. METHODS: The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e. RESULTS: Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments. CONCLUSIONS: SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.

SAMe: efficacy
SAMe as an antidepressant
SAMe (SAMe): bioavailability and safety
Methionine, S-adenosyl-l-methionine (SAMe) and the brain
SAMe (S-adenosyl-L-methionine) versus imipramine (Tofranil)

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family